The combination of raised guidance, strong non-GAAP revenue growth, and upcoming R&D catalysts (remlifanserin Phase 2 readout in Q3 2026) suggests continued momentum. Traders should monitor DAYBUE STIX launch execution in Q2 and pipeline developments as potential upside catalysts.
ACAD drugs
ACAD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $24.64entry
- T+1 · 9mo ago −0.32%α +0.13% · $24.56
- T+5 · 9mo ago −9.09%α −7.96% · $22.40
- T+20 · 8mo ago −12.87%α −6.46% · $21.47
- T+60 · 6mo ago −13.47%α −21.22% · $21.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 results, with GAAP revenue growth of 9% and 12% respectively, and non-GAAP adjusted revenue growth of 16% and 14%. The company raised full year 2026 revenue guidance to $1.22–1.28 billion, driven by continued momentum in NUPLAZID and DAYBUE sales, while also announcing a strategic sales force expansion and upcoming catalysts in its R&D pipeline.
Key Financial Metrics
Key Facts
- Q4 2025 GAAP total revenue: $284 million (9% YoY growth); full year 2025 GAAP revenue: $1.07 billion (12% YoY growth)
- Q4 2025 non-GAAP adjusted revenue: $298 million (16% YoY growth); full year 2025: $1.08 billion (14% YoY growth)
- NUPLAZID GAAP net sales: $174 million in Q4 2025; non-GAAP adjusted: $189 million (17% YoY growth)
- DAYBUE GAAP net sales: $110 million in Q4 2025 (13% YoY growth)
- Full year 2026 revenue guidance: $1.22–1.28 billion, representing 14–19% growth over 2025
- Net income: $274 million in Q4 2025 ($1.60 diluted EPS), up from $144 million ($0.86) in Q4 2024, including a $250 million non-cash tax benefit
- Cash and investments: $820 million at year-end 2025, up from $756 million in 2024
Financial Impact
Revenue growth accelerated in 2025 with full year guidance implying double-digit top-line expansion in 2026. Non-GAAP revenue growth of 14–16% reflects strong underlying demand, particularly for DAYBUE (13% Q4 growth) and NUPLAZID (17% non-GAAP growth).
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| NUPLAZID | $680.1M | +11.7% |
| DAYBUE | $391.4M | +12.4% |
Risk Factors
- GAAP revenue growth was partially impacted by a $20 million non-recurring IRA rebate accrual adjustment for NUPLAZID, which could resurface in future periods
- SG&A expenses increased to $549 million in 2025 and are guided to $660–700 million in 2026, which may pressure margins if revenue growth slows
- Future tax benefits may not be recurring, and core profitability should be assessed excluding the $250 million one-time benefit
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-071674 |
| Document: acad-20260225.htm | 0001193125-26-071674 |
| Document: 0001193125-26-071674-index-headers.html | 0001193125-26-071674 |
| Document: 0001193125-26-071674-index.html | 0001193125-26-071674 |
| Document: 0001193125-26-071674.txt | 0001193125-26-071674 |
| CONTEXT: Previous Earnings (2026-02-25) | 0001193125-26-071674 |
Track record
14 reports on ACAD
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.01% at T+20 after the May 6, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $18.28 Now $18.67 +2.13% settles Dec 9
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $21.24 Now $18.67 −12.10% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $20.57 Now $18.67 −9.24% settles Dec 2
- Oct 23, 202624d ago 8-K Neutral 3/10 Entry $19.74 Now $18.67 −5.42% settles Nov 23
- Sep 24, 20267w ago 8-K Bullish 6/10 Entry $20.68 to $19.73 Now $18.67 −9.72% ▼ −4.59% −3.12% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $27.52 to $19.41 Now $18.67 −32.16% ▼ −29.47% −31.73% vs SPY
- Aug 16, 202613w ago Institutional Cluster Mixed 5/10 Entry $29.01 to $26.76 Now $18.67 −35.64% ▼ −7.76% −5.78% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $29.39 to $27.58 Now $18.67 −36.47% ▼ −6.16% −5.24% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $21.39 to $26.41 Now $18.67 +12.72% ▼ −23.47% −21.58% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $22.56 to $21.43 Now $18.67 +17.24% ▲ +5.01% +8.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers